Metraipolis › archive › dc_2b2fd4b25200

CYP2D6 Pharmacogenetics in Nigerian Sickle Cell Disease: Phase 1 of Implementing Pharmacogenomics Testing for Effective Care and Treatment in Africa… — Europe PMC PMID:41229656

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41229656
DOI
10.12688/gatesopenres.16370.1
License (as archived)
solo-consultazione
Archived
2026-11-08T16:40:44.437Z
SHA-256 of the archived text
c77699c872b9eb41c5ffab68e33cc33958a2f2920e8cb9b9090d6056f74601fd
Stable URL of this page
https://metraipolis.com/documento/dc_2b2fd4b25200

How to cite

CYP2D6 Pharmacogenetics in Nigerian Sickle Cell Disease: Phase 1 of Implementing Pharmacogenomics Testing for Effective Care and Treatment in Africa… — Europe PMC PMID:41229656 — Europe PMC (en), https://europepmc.org/article/MED/41229656 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2b2fd4b25200 (Metraipolis archive dc_2b2fd4b25200, sha256 c77699c872b9eb41c5ffab68e33cc33958a2f2920e8cb9b9090d6056f74601fd)
BibTeX
@misc{dc2b2fd4b25200,
  title = {CYP2D6 Pharmacogenetics in Nigerian Sickle Cell Disease: Phase 1 of Implementing Pharmacogenomics Testing for Effective Care and Treatment in Africa… — Europe PMC PMID:41229656},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41229656},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2b2fd4b25200; sha256 c77699c872b9eb41c5ffab68e33cc33958a2f2920e8cb9b9090d6056f74601fd},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41229656. Agents can read the archived copy with the MCP tool read_document.